Table 1.

Characteristics of 50 randomly selected patients diagnosed with colorectal cancer in Denmark by hospital, 2009–2010

Characteristic	Aarhus University Hospital						Aalborg University Hospital
	Total sample		Chemotherapy received (reference standard)				Total sample		Chemotherapy received (reference standard)
	n	Col %	No	Row %	Yes	Row %	n	Col %	No	Row %	Yes	Row %
	n = 25		n = 7		n = 18		n = 25		n = 8		n = 17
Age, mean (SD)	68 (12)		74 (13)		64 (9)		70 (14)		79 (8)		65 (14)
Female	12	48	4	33	8	67	8	32	2	25	6	75
Colon	15	60	3	20	12	80	11	44	4	36	7	64
Rectum	10	40	4	40	6	60	14	56	4	29	10	71
Tumor invasion
T1	1	4	0	0	1	100	0	0	0	–	0	–
T2	1	4	0	0	1	100	0	0	0	–	0	–
T3	12	48	3	25	9	75	16	64	7	44	9	56
T4	9	36	3	33	6	67	8	32	0	0	8	100
NOS	2	8	1	50	1	50	1	4	1	100	0	0
Nodal involvement
N1	11	44	4	36	7	64	8	32	3	38	5	63
N2	14	56	3	21	11	79	17	68	5	29	12	71
Metastases
M0	15	60	4	27	11	73	18	72	7	39	11	61
M1	9	36	2	22	7	78	6	24	0	0	6	100
NOS	1	4	1	100	0	0	1	4	1	100	0	0
Chemotherapy type
No chemotherapy	7	28					8	32
5-FUa	2	8					8	32
Oxaliplatin-basedb	12	48					3	12
Bevacizumabc	4	16					6	24
Treatment months, mean (SD)d	–		–		4.6 (1)		–		–		4.7 (1)

Notes:

^aIncludes administration of 5-FU or capecitabine alone;

^bincludes administration of oxaliplatin in combination with 5-FU (FOLFOX) or capecitabine (XELOX), but not with bevacizumab;

^cincludes administration of bevacizumab in combination with FOLFOX, XELOX, irinotecan, and 5-FU (FOLFIRI), or 5-FU;

^dbased on pharmacy production data only, excluding patients reporting treatment with capecitabine only in the DNRP.

Abbreviations: Col %, column percentage; DNRP, Danish National Registry of Patients; Row %, row percentage; 5-FU, 5-fluorouracil; NOS, not otherwise specified; SD, standard deviation.